An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007109/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this phase 1/2, open-label study was to evaluate the effect of oral
formulation of Ixazomib when added to standard melphalan and prednisone (MP) treatment. Both
phases of the study included participants who had newly diagnosed multiple myeloma and were
ineligible for high-dose therapy plus stem cell transplantation because of age (≥65 years of
age) or coexisting conditions and for whom standard MP treatment was indicated.
提供机构：
Vivli
创建时间：
2021-05-06
